Partners & Network
Why biosimilars are an opportunity, but could also be a trap.
The Second Wave of Biosimilars. How to find the best ones?
13 recommendations to succeed when selecting 2nd wave biosimilars.
Tenders and long term sustainability of biosimilars in Europe
Biosimilars to increase adoption of biologics in Emerging Markets. Past Evidence for the Future.
At least 255 pharmaceuticals playing biosimilars. Rise of the "Pharmerging" middle class.
Is it true that biosimilars will increase the use of the molecule? Not always...
Commercial strategies for biosimilars: Any sense to register several brands?
Anti TNF biosimilars infliximab and etanercept conquer 63% and 44% of the Top 5 EU in under 3 years.
Biosimilars following same pattern as generics? Neupogen keeps just 6% of EU market after 10 years.
Biosimilars of Rituximab grab 50% market share in top EU markets after less than 2 years.
Notes on the German generics and biosimilars market 2016-2018.
Subscribe to our newsletter and stay in the loop
Thanks for submitting!